{"id":40379,"date":"2024-10-18T10:39:55","date_gmt":"2024-10-18T08:39:55","guid":{"rendered":"https:\/\/www.vismederiholding.com\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/"},"modified":"2024-10-18T10:43:12","modified_gmt":"2024-10-18T08:43:12","slug":"new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera","status":"publish","type":"post","link":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/","title":{"rendered":"Nuova pubblicazione: Advancing Vaccine Research with GVGH – A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera"},"content":{"rendered":"
\n

VisMederi \u00e8 lieta di annunciare la pubblicazione di uno studio in collaborazione con il GVGH (GSK Vaccines Institute for Global Health) che evidenzia un importante risultato nella ricerca sui vaccini. Questo recente studio, pubblicato su Frontiers in Immunology, descrive la creazione e la validazione di un nuovo test di immunoassorbimento enzimatico (ELISA) per quantificare le IgG specifiche per il virus Vi in campioni clinici.<\/p>\n

Rispondere a un’esigenza essenziale<\/b><\/p>\n

I vaccini contro la Salmonella Typhi, l’agente patogeno responsabile della malattia tifoidea, sono essenziali per le iniziative di salute pubblica nelle aree endemiche. Questi vaccini hanno come bersaglio il polisaccaride capsulare Vi, un antigene cruciale che aiuta il sistema immunitario a combattere l’infezione. Con l’integrazione di questi vaccini nei programmi di immunizzazione standard, cresce la richiesta di saggi affidabili, ad alto rendimento ed economici per valutare la risposta immunitaria, in particolare le concentrazioni di IgG specifiche per il Vi nel siero umano.<\/p>\n

Il test:<\/b> Accuratezza ed efficacia<\/b><\/p>\n

La ricerca delinea la validazione di un nuovo ELISA per la misurazione delle IgG specifiche per il virus, mostrandone l’accuratezza, la linearit\u00e0 e la specificit\u00e0. Il saggio \u00e8 stato sottoposto a test approfonditi e confrontato con un ELISA anti-Vi disponibile in commercio, dimostrando prestazioni simili. Il risultato sottolinea la promessa del test come strumento affidabile per valutare le risposte immunitarie nelle indagini cliniche e facilitare lo sviluppo di vaccini.<\/p>\n

Un progresso nel progresso dei vaccini<\/b><\/p>\n

Questo test \u00e8 gi\u00e0 utilizzato per valutare le risposte immunologiche negli studi clinici e mostra un potenziale significativo per far progredire la ricerca in questo campo. Il suo design economico e scalabile garantisce un’implementazione diffusa nei laboratori che eseguono indagini di immunogenicit\u00e0, soprattutto in ambienti con risorse limitate, dove tali strumenti sono necessari in modo critico.<\/p>\n

Per un accesso completo alla pubblicazione e per esaminare l’intricata tecnica e i risultati, si prega di fare riferimento all’articolo qui: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2024.1466869\/full?fbclid=IwY2xjawF9v2hleHRuA2FlbQIxMAABHalCsWQWmCy4vgnmeW8WcEhO7zclGDD99mnxcdVlBTEEJbE-5NugW-InGQ_aem_UmFqkBf8kxHnt9LsUL2YFg<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

VisMederi \u00e8 lieta di annunciare la pubblicazione di uno studio in collaborazione con il GVGH (GSK Vaccines Institute for Global Health) che evidenzia un importante risultato nella ricerca sui vaccini. Questo recente studio, pubblicato su Frontiers in Immunology, descrive la creazione e la validazione di un nuovo test di immunoassorbimento enzimatico (ELISA) per quantificare le […]<\/p>\n","protected":false},"author":3,"featured_media":40377,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[109],"tags":[116,157,170,165,185,128,160,187,135,122,151,155],"dipi_cpt_category":[],"class_list":["post-40379","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newseventi","tag-emanuele-montomoli-it","tag-immunization-it","tag-international-study-it","tag-research-it","tag-serological-testing-it","tag-siena-it","tag-vaccine-it","tag-vaccine-assessment-it","tag-vaccine-development-it","tag-vismederi-it","tag-vismederi-group-it","tag-viusmederi-siena-it"],"yoast_head":"\nNuova pubblicazione: Advancing Vaccine Research with GVGH - A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera - Vismederi Holding<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuova pubblicazione: Advancing Vaccine Research with GVGH - A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera - Vismederi Holding\" \/>\n<meta property=\"og:description\" content=\"VisMederi \u00e8 lieta di annunciare la pubblicazione di uno studio in collaborazione con il GVGH (GSK Vaccines Institute for Global Health) che evidenzia un importante risultato nella ricerca sui vaccini. Questo recente studio, pubblicato su Frontiers in Immunology, descrive la creazione e la validazione di un nuovo test di immunoassorbimento enzimatico (ELISA) per quantificare le […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/\" \/>\n<meta property=\"og:site_name\" content=\"Vismederi Holding\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-18T08:39:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-18T08:43:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2024\/10\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"567\" \/>\n\t<meta property=\"og:image:height\" content=\"567\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Elec23\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elec23\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/\"},\"author\":{\"name\":\"Elec23\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#\\\/schema\\\/person\\\/2001c2c9d347ea0b6f36abac39396e9c\"},\"headline\":\"Nuova pubblicazione: Advancing Vaccine Research with GVGH – A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera\",\"datePublished\":\"2024-10-18T08:39:55+00:00\",\"dateModified\":\"2024-10-18T08:43:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/\"},\"wordCount\":355,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg\",\"keywords\":[\"Emanuele Montomoli\",\"Immunization\",\"International Study\",\"research\",\"Serological Testing\",\"siena\",\"vaccine\",\"Vaccine Assessment\",\"vaccine development\",\"VisMederi\",\"vismederi group\",\"ViusMederi Siena\"],\"articleSection\":[\"News&eventi\"],\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/\",\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/\",\"name\":\"Nuova pubblicazione: Advancing Vaccine Research with GVGH - A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera - Vismederi Holding\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg\",\"datePublished\":\"2024-10-18T08:39:55+00:00\",\"dateModified\":\"2024-10-18T08:43:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#\\\/schema\\\/person\\\/2001c2c9d347ea0b6f36abac39396e9c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg\",\"contentUrl\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg\",\"width\":567,\"height\":567},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuova pubblicazione: Advancing Vaccine Research with GVGH – A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/\",\"name\":\"Vismederi Holding\",\"description\":\"A group with expertise in the evaluation of vaccine immunogenicity\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#\\\/schema\\\/person\\\/2001c2c9d347ea0b6f36abac39396e9c\",\"name\":\"Elec23\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g\",\"caption\":\"Elec23\"},\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/author\\\/elec23\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuova pubblicazione: Advancing Vaccine Research with GVGH - A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera - Vismederi Holding","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/","og_locale":"it_IT","og_type":"article","og_title":"Nuova pubblicazione: Advancing Vaccine Research with GVGH - A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera - Vismederi Holding","og_description":"VisMederi \u00e8 lieta di annunciare la pubblicazione di uno studio in collaborazione con il GVGH (GSK Vaccines Institute for Global Health) che evidenzia un importante risultato nella ricerca sui vaccini. Questo recente studio, pubblicato su Frontiers in Immunology, descrive la creazione e la validazione di un nuovo test di immunoassorbimento enzimatico (ELISA) per quantificare le […]","og_url":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/","og_site_name":"Vismederi Holding","article_published_time":"2024-10-18T08:39:55+00:00","article_modified_time":"2024-10-18T08:43:12+00:00","og_image":[{"width":567,"height":567,"url":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2024\/10\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg","type":"image\/jpeg"}],"author":"Elec23","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Elec23","Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/#article","isPartOf":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/"},"author":{"name":"Elec23","@id":"https:\/\/www.vismederiholding.com\/it\/#\/schema\/person\/2001c2c9d347ea0b6f36abac39396e9c"},"headline":"Nuova pubblicazione: Advancing Vaccine Research with GVGH – A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera","datePublished":"2024-10-18T08:39:55+00:00","dateModified":"2024-10-18T08:43:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/"},"wordCount":355,"commentCount":0,"image":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/#primaryimage"},"thumbnailUrl":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2024\/10\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg","keywords":["Emanuele Montomoli","Immunization","International Study","research","Serological Testing","siena","vaccine","Vaccine Assessment","vaccine development","VisMederi","vismederi group","ViusMederi Siena"],"articleSection":["News&eventi"],"inLanguage":"it-IT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/","url":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/","name":"Nuova pubblicazione: Advancing Vaccine Research with GVGH - A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera - Vismederi Holding","isPartOf":{"@id":"https:\/\/www.vismederiholding.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/#primaryimage"},"image":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/#primaryimage"},"thumbnailUrl":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2024\/10\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg","datePublished":"2024-10-18T08:39:55+00:00","dateModified":"2024-10-18T08:43:12+00:00","author":{"@id":"https:\/\/www.vismederiholding.com\/it\/#\/schema\/person\/2001c2c9d347ea0b6f36abac39396e9c"},"breadcrumb":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/#primaryimage","url":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2024\/10\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg","contentUrl":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2024\/10\/Immagine-WhatsApp-2024-10-16-ore-14.49.21_b9cc9393.jpg","width":567,"height":567},{"@type":"BreadcrumbList","@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-advancing-vaccine-research-with-gvgh-a-novel-assay-for-quantifying-anti-vi-igg-in-clinical-sera\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vismederiholding.com\/it\/"},{"@type":"ListItem","position":2,"name":"Nuova pubblicazione: Advancing Vaccine Research with GVGH – A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera"}]},{"@type":"WebSite","@id":"https:\/\/www.vismederiholding.com\/it\/#website","url":"https:\/\/www.vismederiholding.com\/it\/","name":"Vismederi Holding","description":"A group with expertise in the evaluation of vaccine immunogenicity","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vismederiholding.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Person","@id":"https:\/\/www.vismederiholding.com\/it\/#\/schema\/person\/2001c2c9d347ea0b6f36abac39396e9c","name":"Elec23","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g","caption":"Elec23"},"url":"https:\/\/www.vismederiholding.com\/it\/author\/elec23\/"}]}},"_links":{"self":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts\/40379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/comments?post=40379"}],"version-history":[{"count":2,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts\/40379\/revisions"}],"predecessor-version":[{"id":40381,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts\/40379\/revisions\/40381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/media\/40377"}],"wp:attachment":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/media?parent=40379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/categories?post=40379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/tags?post=40379"},{"taxonomy":"dipi_cpt_category","embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/dipi_cpt_category?post=40379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}